ECRON-ACUNOVA
4.12.2015 10:24:06 CET | Business Wire | Press release
Anders Malm, Managing Director of Ecron Acunova and responsible for operations in Europe and North America is pleased to announce that Erik Carp has joined Ecron Acunova as Leader Nordic Region.
Erik Carp joined Ecron Acunova in November with responsibility for the Nordic Region. He will bring much operational experience from local and multinational clinical trials within different therapeutic areas. With a Master in pharmacy from Copenhagen University and a Bachelor in business administration from Copenhagen Business School, Erik Carp brings about 25 years of international clinical operations and business experience from pharmaceutical and biotech companies to Ecron Acunova.
Ecron Acunova (www.ecronacunova.com ) is an expert CRO with over 25 years of track record covering 19 European countries, 9 Asian countries and the United States and Canada. It offers full service clinical research including clinical operations, data management, biostatistics, pharmacovigilance, medical writing, PK/PD services and central laboratory services to pharma, biotech, medical device, nutrition and diagnostic companies. Ecron Acunova operates each region as a priority market with European HQ in Frankfurt, Asian HQ in Singapore, and US HQ in Princeton. With a team of over 350 professionals including about 70 MDs and PhDs, Ecron Acunova is reputed to accelerate pharma time‐to‐market cost effectively.
Speaking on the appointment, Anders Malm, CEO Ecron Acunova Europe, said, “Mr. Carp brings extensive experience in clinical research and he has worked with several CROs over the years as a sponsor. With his experience, Erik Carp can contribute to ensuring that Ecron Acunova’s services continue to meet the specific needs of each our sponsors in terms of quality, timing and budgets. We will continue to serve existing clients and build close relations with biotech and pharmaceutical companies for global as well as local services”.
On his appointment, Mr. Carp said, “Ecron Acunova is a CRO with vast experience within many therapeutic areas. With a highly trained staff in three continents Ecron Acunova has a knowledge base which is unique for a CRO of our size. The company has a global reach, while at the same time we can take care of clients on a local and personal basis. The right size matters in this industry and Ecron Acunova can adapt to the size of each of the sponsors we serve. In our organization, each employee can contribute to the success of our sponsors, make a real difference every day, be visible, accountable and constantly strengthen and develop existing and new competencies. It is a pleasure and privilege for me to be part of Ecron Acunova”.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151204005233/en/
Contact:
Ecron Acunova Europe HQ
Anders Malm
anders.malm@ecronacunova.com
+49
69 6680 300
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
